Loading...
XJPX
7774
Market cap131mUSD
Dec 05, Last price  
502.00JPY
1D
-0.99%
1Q
0.00%
Jan 2017
-65.36%
IPO
13.06%
Name

Japan Tissue Engineering Co Ltd

Chart & Performance

D1W1MN
XJPX:7774 chart
P/E
—
P/S
8.30
EPS
—
Div Yield, %
—
Shrs. gr., 5y
—
Rev. gr., 5y
1.23%
Revenues
2.46b
-2.34%
111,752,000114,724,000211,659,000351,574,000473,606,000563,704,0001,008,044,0001,321,494,0001,430,826,0002,135,148,0002,271,506,0002,357,917,0002,309,851,0002,257,609,0002,103,443,0002,032,448,0002,514,189,0002,455,474,000
Net income
-255m
L
-1,086,238,000-1,133,985,000-1,099,917,000-1,156,986,000-1,096,366,000-1,077,686,000-827,837,000-690,527,000-681,539,000276,242,000227,890,000-333,248,000-287,099,000-466,622,000-497,889,000-729,317,000143,169,000-255,304,000
CFO
-148m
L
-981,718,000-1,021,897,000-1,021,005,000-1,012,151,000-1,059,155,000-989,987,000-961,315,000-756,723,000-346,906,00054,950,000632,006,000-396,110,000-84,584,000-399,586,000-225,248,000-622,600,000274,138,000-148,365,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Japan Tissue Engineering Co., Ltd. engages in the regenerative medicine business in Japan. The company operates through Regenerative Medicine Product, Regenerative Medicine Outsourcing, and Research and Development Support segments. It offers autologous cultured epidermis, cartilage, corneal epithelium, and oral mucosal epithelium to medical institutions for the purpose of medical treatment. The company also provides tissue-engineered medical products. In addition, it researches and develops human 3-dimensional cultured tissue models for use in the development of cosmetics and drugs for external use, as well as in research that employs skin and cornea tissues. Further, the company offers regenerative medicine contract development and manufacturing services. The company was founded in 1999 and is headquartered in Gamagori, Japan. Japan Tissue Engineering Co., Ltd. is a subsidiary of Teijin Limited.
URL
https://www.jpte.co.jp/
IPO date
Dec 21, 2007
Employees
Domiciled in
JP
Incorporated in
JP

Valuation

Title
JPY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑032024‑032023‑032022‑032021‑032020‑032019‑032018‑032017‑032016‑03
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT